Contracts & Pricing August 13, 2021 Compliance Guidelines for Government Programs 5 Minute Read Six key elements to operate an effective compliance program. Also, new VA FSS rules for vaccine drugs, State Price Transparency, and Medicare Part D updates and reminders.
Contracts & Pricing July 26, 2021 The Branded Pharma Fee Deadline Approaches 4 Minute Read We'll tell you how to prepare. Plus new manufacturer awareness for orphan drugs, midnight changes to MDRP, and upholding the ACA.
Contracts & Pricing June 29, 2021 SPTR, CMS Final Rule & VA Public Law Updates 5 Minute Read The latest regulatory updates and reporting reminders for June 2021.
Contracts & Pricing May 27, 2021 Making Sense of Co-Pay Offset Programs 4 Minute Read We dive into the specifics of co-pay offset programs and also examine updates to 340B administrative dispute resolution and ASP reporting as per H.R. 133.
Contracts & Pricing April 21, 2021 Updates to State Price Transparency Reporting, Medicaid Laws 3 Minute Read Stay up-to-date with relevant, timely industry insights and regulatory updates that may impact pharmaceutical manufacturers.
Contracts & Pricing April 14, 2021 The Current State of Pharmaceutical Price Transparency Reporting 2 Minute Read What you need to know about navigating a patchwork of state policies, achieving operational readiness, and avoiding compliance risk.
Contracts & Pricing March 11, 2021 Changes to Medicare Part D, Drug Rebate Program, OIG Final Rule 5 Minute Read Stay up-to-date with relevant, timely industry insights and regulatory updates that may impact pharmaceutical manufacturers.
Contracts & Pricing February 16, 2021 New ASP Reporting Requirements, 340B Drug Pricing Program and Final Rule,... 4 Minute Read Stay up-to-date with relevant, timely industry insights and regulatory updates that may impact pharmaceutical manufacturers.
Contracts & Pricing October 15, 2020 Public Law Timeline for 2021, OIG Audit Report, Hot Topics at... 2 Minute Read Stay up-to-date with relevant, timely industry insights and regulatory updates that may impact pharmaceutical manufacturers.
